Navigation Links
New drug candidate prolongs the lives of pancreatic cancer patients
Date:7/20/2009

Every year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than 5% are still alive five years after diagnosis.

There's new hope, though, from the lab of Prof. Yoel Kloog, dean of Tel Aviv University's Faculty of Life Sciences. His drug compound Salirasib has shown positive results against pancreatic cancer and recently passed Phase I/II clinical trials. The drug, given in combination with gemcitabine, the standard drug used to combat pancreatic cancer, almost doubled the life expectancy of those who received it.

"In our study, the mean survival of pancreatic cancer patients was 10.8 months better by far than the 6.2 months with gemcitabine alone," says Prof. Kloog, who recently presented the results to a meeting of the American Society of Clinical Oncology. His basic research offers the promise of a weapon to attack a broader range of mankind's most prevalent diseases, including lung, prostate and breast cancers as well as diabetes.

Blocking the Ras protein

Salirasib works by inhibiting a protein called Ras, which is known to be abnormally activated in one-third of human cancers. In cancer of the pancreas, mutant forms of Ras are found in up to 90% of all tumors. Salirasib's basic component, FTS, works to block the formation of cancer-promoting Ras nanoclusters, thus blocking a cascade of biochemical signals known as the "Ras signaling pathway" that allow Ras to wreak havoc on the body.

Early in the 1990s, many drug developers chased after a mechanism to inhibit Ras by targeting enzymes that modify it, but they were unsuccessful. "The major developers gave up, claiming Ras is not targetable," says Prof. Kloog, "but our concept takes a different approach. Now that we've shown it works in human subjects, I am definitely excited no doubt about it." Prof. Kloog developed the Ras antagonist more than 15 years ago.

No toxic side effects

In the lates
'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Some Epilepsy Patients Are Good Candidates for Surgery
2. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. U.S. Physicians Question Presidential Candidates
5. Schizophrenia candidate genes affect even healthy individuals
6. Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
9. 1 in 5 bariatric surgery candidates not psychologically cleared for surgery
10. Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... New York, New York (PRWEB) September 18, 2014 ... dozen Xarelto lawsuits ( http://www.xareltolawsuitcenter.com ) currently pending ... attempting to have all claims filed on behalf ... According to motions filed on September 11th, the ... and other claims contained in the lawsuits have ...
(Date:9/18/2014)... Kent, WA Chiropractor Danene Saggau and the ... that Dawn Kelly has agreed to become the new Office ... to Ms. Kelly expanding her role within the practice, noting ... key contributor. “ Dawn Kelly brings to the clinic ... that will allow me to focus on the patient ...
(Date:9/18/2014)... Dr. David A. F. Ellis is a Board ... Facial Plastic and Reconstructive Surgery and a Professor at ... Plastic Surgery. He is recognized around the world ... Dr. Ellis will be presenting on numerous injectable topics. ... techniques and various treatments for complications associated with injectable ...
(Date:9/18/2014)... September 18, 2014 Alexandria, VA — ... today that 10 more communities have joined the growing ... health department accreditation. The decisions bring the number of ... 54. PHAB is the non-profit organization that administers the ... and protect the health of the public by advancing ...
(Date:9/18/2014)... (HealthDay News) -- Exposure to diverse communities may boost ... Hearing different languages in the park or supermarket ... from people who are different from them, researchers found. ... are often biased against interacting with and learning from ... a University of Chicago psychology professor, said in a ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2
... , , , INDIANAPOLIS, ... been named by Adventist Health System as its exclusive clearinghouse ... utilize RealMed,s portal-based clearinghouse/Revenue Cycle Management Services to improve Adventist ... , , (Logo: ...
... , , , ... development-stage pharmaceutical company discovering and developing novel RNA interference ... Vice President, Pharmaceutical Development, will participate in multiple roles ... The conference will take place August 3-5, 2009 in ...
... , , HATBORO, Pa., ... IFLG ), a leading technology provider of enterprise ... the introduction of a new mobility offering for healthcare providers, ... solution that enables medical professionals to access critical patient information ...
... , , , ... August 3 Zogenix, Inc. ("Zogenix"), a privately held ... today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan ... approval in July 2009 and is a first-of-its-kind needle-free ...
... skills increase the risk of trouble, expert says, , MONDAY, ... ramping up physical education programs to battle the childhood obesity ... has risen dramatically, Ohio State University researchers report. , ... injuries related to physical education (PE) increased 150 percent -- ...
... published in the August issue of The Journal of ... an important tool for depicting the extent of neuroblastoma in ... the disease. Neuroblastoma accounts for six to ten percent of ... of cancer deaths in children. Accurately identifying where in the ...
Cached Medicine News:Health News:RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System 2Health News:RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System 3Health News:Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference 2Health News:Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference 3Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 2Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 4Health News:Gym Class Injuries Up 150 Percent 2Health News:Gym Class Injuries Up 150 Percent 3Health News:PET can help guide treatment decisions for a common pediatric cancer 2
(Date:9/18/2014)... After 6 months of careful research ... - the new programme for the next Cool Chain & ... global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and purchasing ... is broad and yet specific, focused and yet accessible, inclusive ...
(Date:9/18/2014)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... RNA viruses, today announced a research collaboration with ... testing of the Company,s lead compound, SB 9200, ... against which currently there are no effective antiviral ... proprietary Small Molecule Nucleic Acid Hybrid (SMNH) ...
(Date:9/18/2014)... ROCKVILLE, Md. , Sept. 18, 2014 ... a biotechnology company with fully integrated commercial and drug ... oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary focus on China , announce ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10
Bipolar foot activated forceps....
Bipolar forceps 6.7 cm 2-11/16" or 3/32" (bent) coated....
Blunt, with attached cable for Valleylab and other brands generators....
Blunt, 20 cm long....
Medicine Products: